ABIVAX confirms trading suspension

Paris, April 28th at 5:00pm CEST – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, confirms the suspension of trading on Euronext Paris effective as of April 28, 2017 at 11:29am CEST.

This suspension was requested upon observation of unusual and significant variations on the stock exchange. Given this context, the company has decided, in agreement with the AMF (French Market Authority), to suspend trading.

Trading will resume on May 2nd, 2017 before the opening of the Paris stock exchange. ABIVAX also confirms that the results of ABX464-004, the 2nd Phase IIa clinical trial of ABX464, its lead drug candidate in the treatment of HIV, will be disclosed on May 2nd before market opening, as initially planned. 

Press contacts

Caroline Carmagnol 


+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41